Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aethlon MedicalAEMD -1.57%19 EV-to-EBITDA is 0.45 as of Aug. 11, 2026, which is 25% above its 10-year median of 0.36. GuruFocus rates AEMD with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 516 Medical Devices & Instruments companies, Aethlon Medical ranks better than 97.48% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aethlon Medical's enterprise value is $-3.07 Mil.
Aethlon Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.81 Mil. Therefore, Aethlon Medical's EV-to-EBITDA for today is 0.45.
The historical rank and industry rank for Aethlon Medical's EV-to-EBITDA or its related term are showing as below:
AEMD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -11.96 Med: 0.36 Max: 1.04
Current: 0.45
During the past 13 years, the highest EV-to-EBITDA of Aethlon Medical was 1.04. The lowest was -11.96. And the median was 0.36.
AEMD's EV-to-EBITDA is ranked better than 97.48% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 14.81
vs AEMD: 0.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aethlon Medical (NAS:AEMD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aethlon Medical's PE Ratio (TTM) for today is calculated as:
Aethlon Medical's share price for today is $3.08.
Aethlon Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-247.749.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aethlon Medical's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Aethlon Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aethlon Medical EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aethlon Medical's EV-to-EBITDA falls into.
Aethlon Medical's current Enterprise Value is $-3.07 Mil.
Aethlon Medical's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aethlon Medical (AEMD) has a EV-to-EBITDA of 0.45 as of Aug. 11, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aethlon Medical. This is 25% above median its historical median of 0.36. According to the industry distribution chart, Aethlon Medical ranks #13 out of 516 companies in the Medical Devices & Instruments industry, placing it in the top 2.5%.
Is Aethlon Medical's EV-to-EBITDA too high?
Aethlon Medical's current EV-to-EBITDA of 0.45 is 25% above median its 10-year median of 0.36. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.81. Aethlon Medical's value of 0.45 is 97% below this industry median. Based on the distribution chart, Aethlon Medical ranks #13 out of 516 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aethlon Medical has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's EV-to-EBITDA compare to NUMD and AMIX?
According to the Medical Devices & Instruments industry distribution chart, Aethlon Medical ranks #13 out of 516 companies for EV-to-EBITDA. This places Aethlon Medical in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-EBITDA is 14.81. Aethlon Medical's value of 0.45 is 97% below this benchmark. While the company's 10-year median is 0.36 vs. the industry median of 14.81, Aethlon Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.81, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aethlon Medical's current EV-to-EBITDA of 0.45 is 97% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aethlon Medical. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aethlon Medical's current EV-to-EBITDA is 0.45, which is 25% above median its own 10-year median of 0.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current EV-to-EBITDA of 0.45. The current EV-to-EBITDA is 0.45, which is 25% above median its 10-year median of 0.36 and 97% below the Medical Devices & Instruments industry median of 14.81. Aethlon Medical's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current EV-to-EBITDA is 0.45 as of Aug. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
19GF Score
Get the complete analysis for AEMD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AEMD has been successfully added to your 
